ES2284275T3
(es)
*
|
1998-06-30 |
2007-11-01 |
Om Pharma |
Nuevos pseudodipeptidos acilados, su procedimientos de preparacion y las composiciones farmaceuticas que los incluyen.
|
AU757507B2
(en)
|
1999-02-10 |
2003-02-20 |
Sankyo Company Limited |
Ether type lipid A1-carboxylic acid analogues
|
NZ513935A
(en)
|
1999-02-17 |
2004-02-27 |
Csl Ltd |
Immunogenic complexes and methods relating thereto
|
WO2001036433A2
(en)
*
|
1999-11-15 |
2001-05-25 |
Biomira, Inc. |
Synthetic lipid-a analogs and uses thereof
|
KR100898844B1
(ko)
*
|
1999-12-22 |
2009-05-21 |
옴 파르마 |
작용기화된 보조 아암을 가진 아실 슈도디펩티드
|
WO2001046127A1
(fr)
*
|
1999-12-22 |
2001-06-28 |
Om Pharma |
Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
|
US20050019340A1
(en)
|
2000-10-18 |
2005-01-27 |
Nathalie Garcon |
Vaccines
|
KR100465229B1
(ko)
*
|
2001-04-09 |
2005-01-13 |
주식회사 안지오랩 |
2-아미노-2-데옥시-d-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
|
WO2004030608A2
(en)
*
|
2001-06-05 |
2004-04-15 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
JP5404990B2
(ja)
|
2002-10-23 |
2014-02-05 |
グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム |
マラリアに対するワクチン接種の方法
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
DE602005025342D1
(de)
|
2004-05-28 |
2011-01-27 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
WO2006095270A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Om Pharma |
Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
|
WO2006011007A1
(en)
*
|
2004-07-23 |
2006-02-02 |
Om Pharma |
Combination anticancer therapy and pharmaceutical compositions therefore
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20060210590A1
(en)
|
2005-02-03 |
2006-09-21 |
Alk-Abello A/S |
Minor allergen control to increase safety of immunotherapy
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ561823A
(en)
|
2005-03-23 |
2010-04-30 |
Glaxosmithkline Biolog Sa |
Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
|
CN101378778B
(zh)
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2476433A1
(en)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
KR100780868B1
(ko)
*
|
2006-07-10 |
2007-11-30 |
부경대학교 산학협력단 |
항암효과를 나타내는 4급 아미노 글루코사민 화합물
|
PT2043682E
(pt)
|
2006-07-17 |
2014-07-11 |
Glaxosmithkline Biolog Sa |
Vacina da influenza
|
NZ574239A
(en)
|
2006-07-18 |
2011-12-22 |
Glaxosmithkline Biolog Sa |
Hybrid fusion proteins for malaria vaccines
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
SI2068918T1
(sl)
|
2006-09-26 |
2012-09-28 |
Infectious Disease Res Inst |
Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
|
EP2086582B1
(en)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Vaccine comprising an oil in water emulsion adjuvant
|
WO2008059307A2
(en)
*
|
2006-11-16 |
2008-05-22 |
Om Pharma |
Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
|
SI2137210T1
(sl)
|
2007-03-02 |
2017-01-31 |
Glaxosmithkline Biologicals S.A. |
Nov postopek in sestavki
|
BRPI0808333B8
(pt)
|
2007-03-05 |
2021-05-25 |
Om Pharma |
extrato bacteriano para doenças respiratórias e processo para sua preparação
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
SI2222710T1
(sl)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Rekombinatni RSV antigeni
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
THE VACCINE
|
US20090291095A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Nanoemulsion adjuvants
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
CA2735724C
(en)
|
2008-06-19 |
2018-07-24 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
CN102325790A
(zh)
|
2008-12-03 |
2012-01-18 |
西马生物医学计划公司 |
应用酚可溶性调控蛋白研制疫苗
|
WO2010079081A1
(en)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Methods for recovering a virus or a viral antigen produced by cell culture
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
EP2393922A1
(en)
|
2009-02-06 |
2011-12-14 |
GlaxoSmithKline Biologicals S.A. |
Purification of virus or viral antigens by density gradient ultracentrifugation
|
WO2010094663A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxosmithkline Biologicals S.A. |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US20110097418A1
(en)
*
|
2009-05-29 |
2011-04-28 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
US20100316673A1
(en)
*
|
2009-06-16 |
2010-12-16 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
CA2766211A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
CA2767392C
(en)
|
2009-07-06 |
2017-03-14 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
WO2011036220A1
(en)
|
2009-09-25 |
2011-03-31 |
Glaxosmithkline Biologicals S.A. |
Immunodiffusion assay for influenza virus
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
WO2011116262A2
(en)
*
|
2010-03-19 |
2011-09-22 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating urinary tract infections
|
ES2562818T3
(es)
|
2010-05-03 |
2016-03-08 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de inactivación del virus de la gripe
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
AU2011315447A1
(en)
|
2010-10-15 |
2013-05-09 |
Glaxosmithkline Biologicals S.A. |
Cytomegalovirus gB antigen
|
AU2012205315B2
(en)
|
2011-01-13 |
2017-05-04 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
WO2012097346A1
(en)
|
2011-01-13 |
2012-07-19 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
MX350795B
(es)
|
2011-04-08 |
2017-09-19 |
Inmune Design Corp |
Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
PT2758432T
(pt)
|
2011-09-16 |
2019-06-14 |
Ucb Biopharma Sprl |
Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2802353A4
(en)
|
2012-01-12 |
2015-12-02 |
Variation Biotechnologies Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
US9518078B2
(en)
*
|
2012-04-12 |
2016-12-13 |
Avanti Polar Lipids, Inc. |
Disaccharide synthetic lipid compounds and uses thereof
|
US9241988B2
(en)
*
|
2012-04-12 |
2016-01-26 |
Avanti Polar Lipids, Inc. |
Disaccharide synthetic lipid compounds and uses thereof
|
PT2850431T
(pt)
|
2012-05-16 |
2018-07-23 |
Immune Design Corp |
Vacinas para hsv-2
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
JP6426706B2
(ja)
|
2013-04-18 |
2018-11-21 |
イミューン デザイン コーポレイション |
がん処置で使用するためのgla単剤療法
|
US11052142B2
(en)
*
|
2013-06-04 |
2021-07-06 |
Petr G. Aparin |
Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
|
EA031879B1
(ru)
*
|
2013-06-04 |
2019-03-29 |
Пётр Геннадиевич Апарин |
Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
BE1022008B1
(fr)
|
2013-08-05 |
2016-02-03 |
Glaxosmithkline Biologicals S.A. |
Compositions immunogenes combinees
|
ES2778928T3
(es)
|
2013-08-30 |
2020-08-12 |
Glaxosmithkline Biologicals Sa |
Producción a gran escala de virus en cultivos celulares
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
JP6306700B2
(ja)
|
2013-11-01 |
2018-04-04 |
ユニバーシティ オブ オスロUniversity of Oslo |
アルブミン改変体及びその使用
|
EP3069138B1
(en)
|
2013-11-15 |
2019-01-09 |
Oslo Universitetssykehus HF |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
EP4226937A3
(en)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
WO2016207730A1
(en)
|
2015-06-22 |
2016-12-29 |
The University Of Oslo |
Targeting of vaccine antigen to an intracellular compartment
|
WO2016207408A1
(en)
|
2015-06-26 |
2016-12-29 |
Institute For Research In Biomedicine |
Novel vaccines in prevention and treatment of malaria
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
CA3011887A1
(en)
|
2016-03-14 |
2017-09-21 |
Stian FOSS |
Engineered immunoglobulins with altered fcrn binding
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
EP3504230A1
(en)
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
EP3638301A1
(en)
|
2017-06-16 |
2020-04-22 |
GlaxoSmithKline Biologicals S.A. |
Method of treatment
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
MX2020008417A
(es)
|
2018-02-12 |
2020-11-11 |
Inimmune Corp |
Ligandos de receptores de tipo toll.
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
CN112601545A
(zh)
|
2018-08-07 |
2021-04-02 |
葛兰素史密丝克莱恩生物有限公司 |
工艺和疫苗
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
WO2020178359A1
(en)
|
2019-03-05 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Hepatitis b immunisation regimen and compositions
|
WO2021014385A1
(en)
|
2019-07-24 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
IL303334A
(en)
|
2020-12-02 |
2023-07-01 |
Glaxosmithkline Biologicals Sa |
The perfect fimh by a donor strand
|
WO2022162012A2
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
WO2022161598A1
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2023144665A1
(en)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|